Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper

Vaccine

Volumn 30, Issue 34, 2012, Pages 5067-5072

  Wang, Xijun ^a   Feng, Na ^b   Ge, Jinying ^a   Shuai, Lei ^a   Peng, Liyan ^a   Gao, Yuwei ^b   Yang, Songtao ^b   Xia, Xianzhu ^b   Bu, Zhigao ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Canine distemper; Rabies; Recombinant canine distemper virus; Vaccine

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; RABIES VIRUS GLYCOPROTEIN; RECOMBINANT CANINE DISTEMPER VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANINE DISTEMPER; CANINE DISTEMPER MORBILLIVIRUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; VACCINATION; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DISTEMPER; DISTEMPER VIRUS, CANINE; DOGS; GENES, VIRAL; GLYCOPROTEINS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; PLASMIDS; RABIES; RABIES VIRUS; REVERSE GENETICS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 84863782365     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.001     Document Type: Article

References (29)

1. Ming P., Du J., Tang Q., Yan J., Nadin-Davis S.A., Li H., et al. Molecular characterization of the complete genome of a street rabies virus isolated in China. Virus Res 2009, 143(1):6-14.
2. Jackson A.C., Wunner W.H. Rabies 2007, Elsevier/Academic Press, Amsterdam/Boston. 2nd ed.
3. Osinubi M.O., Wu X., Franka R., Niezgoda M., Nok A.J., Ogunkoya A.B., et al. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine 2009, 27(51):7214-7218.
4. World Health Organization WHO expert consultation on rabies: first report 2005, World Health Organization, Geneva.
5. Martinez L. Global infectious disease surveillance. Int J Infect Dis 2000, 4(4):222-228.
6. Ge J., Wang X., Tao L., Wen Z., Feng N., Yang S., et al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol 2011, 85(16):8241-8252.
7. Fu Z.F. Rabies and rabies research: past, present and future. Vaccine 1997, 15(Suppl):S20-S24.
8. Lembo T., Hampson K., Kaare M.T., Ernest E., Knobel D., Kazwala R.R., et al. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl Trop Dis 2010, 4(2):e626.
9. Brown A.L., Vitamvas J.A., Merry D.L., Beckenhauer W.H. Immune response of pups to modified live-virus canine distemper-measles vaccine. Am J Vet Res 1972, 33(7):1447-1456.
10. Cherpillod P., Tipold A., Griot-Wenk M., Cardozo C., Schmid I., Fatzer R., et al. DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper. Vaccine 2000, 18(26):2927-2936.
11. Appel M.J. Pathogenesis of canine distemper. Am J Vet Res 1969, 30(7):1167-1182.
12. Silin D., Lyubomska O., Ludlow M., Duprex W.P., Rima B.K. Development of a challenge-protective vaccine concept by modification of the viral RNA-dependent RNA polymerase of canine distemper virus. J Virol 2007, 81(24):13649-13658.
13. Ek-Kommonen C., Rudbäck E., Anttila M., Aho M., Huovilainen A. Canine distemper of vaccine origin in European mink, Mustela lutreola-a case report. Vet Microbiol 2003, 92(3):289-293.
14. Ge J., Tian G., Zeng X., Jiang Y., Chen H., Bu Z. Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Avian Dis 2010, 54(Suppl 1):294-296.
15. Ge J., Deng G., Wen Z., Tian G., Wang Y., Shi J., et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 2007, 81(1):150-158.
16. Johnson N., Mansfield K.L., Fooks A.R. Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein. J Gen Virol 2002, 83(11):2663-2669.
17. Dietzschold B., Li J., Faber M., Schnell M. Concepts in the pathogenesis of rabies. Future Virol 2008, 3(5):481-490.
18. Reed L., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
19. Tao L., Ge J., Wang X., Zhai H., Hua T., Zhao B., et al. Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation. J Virol 2010, 84(17):8926-8936.
20. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 1973, 48(5):535.
21. Faber M., Pulmanausahakul R., Nagao K., Prosniak M., Rice A.B., Koprowski H., et al. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci U S A 2004, 101(46):16328-16332.
22. Kanesa-thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000, 19(4-5):483-491.
23. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 2001, 82(9):2215-2223.
24. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003, 77(1):799-803.
25. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81(12):6594-6604.
26. Weingartl H.M., Berhane Y., Caswell J.L., Loosmore S., Audonnet J.C., Roth J.A., et al. Recombinant Nipah virus vaccines protect pigs against challenge. J Virol 2006, 80(16):7929-7938.
27. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(4):1959-1964.
28. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007, 81(12):6379-6388.
29. Chen W., Hu S., Qu L., Hu Q., Zhang Q., Zhi H., et al. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep. Vaccine 2010, 28(30):4742-4750.